Abstract HIV-associated neurocognitive disorder affects about half of HIV-infected patients. HIV impairs neuronal function through indirect mechanisms mainly mediated by inflammatory cytokines and neurotoxic viral proteins, such as the envelope protein gp120. HIV gp120 elicits a neuroinflammatory response that potentiates NMDA receptor function and induces the loss of excitatory synapses. How gp120 influences neuronal inhibition remains unknown. In this study, we expressed a green fluorescent protein (GFP)-tagged recombinant antibody-like protein that binds to the post-synaptic scaffolding protein gephyrin to label inhibitory synapses in living neurons. Treatment with 600 pM gp120 for 24 h increased the number of labeled inhibitory synapses. HIV gp120 evoked the release of interleukin-1b (IL-1b) from microglia to activate IL-1 receptors on neurons. Subsequent activation of the tyrosine kinase Src and GluN2A-containing NMDA receptors increased the number of inhibitory synapses via a process that required protein synthesis. In na€ ıve cultures, inhibition of neuronal p38 mitogen-activated protein kinase (p38 MAPK) increased the number of inhibitory synapses suggesting that p38 MAPK produces a basal suppression of inhibitory synapses that is overcome in the presence of gp120. Direct activation of a mutant form of p38 MAPK expressed in neurons mimicked basal suppression of inhibitory synapses. This study shows for the first time that gp120-induced neuroinflammation increases the number of inhibitory synapses and that this increase overcomes a basal suppression of synaptic inhibition. Increased inhibition may be an adaptive mechanism enabling neurons to counteract excess excitatory input in order to maintain network homeostasis.
HIV-associated neurocognitive disorder (HAND) affects about half of the over 36 million people infected (Saylor et al. 2016) . Although broad application of combination antiretroviral therapy has dramatically reduced the number of patients that progress to AIDS, combination antiretroviral therapy does not eradicate HIV from the brain (Ellis et al. 2007; Saylor et al. 2016) . Thus, the prevalence of HAND remains high, in part because of the increased lifespan of HIV-infected individuals (Eggers et al. 2017) . Currently there is no effective treatment for HAND.
Chronic neuroinflammation is a major component of HAND pathogenesis Gill and Kolson 2014; Walsh et al. 2014; Hong and Banks 2015) . HIVinfected macrophages and microglia release viral proteins and cytokines eliciting an inflammatory response that disturbs neuronal network activity and causes progressive loss of cognitive function (Ellis et al. 2007) . In response to excess excitatory drive produced by HIV-associated neuroinflammation, neurons decrease the number of excitatory synapses (Bellizzi et al. 2006; Kim et al. 2008a; Green et al. 2018; Guha et al. 2018) . Loss of excitatory synapses correlates with cognitive decline in HAND (Ellis et al. 2007) . Normal network activity requires balanced excitatory and inhibitory neurotransmission (Pozo and Goda 2010) . Changes in inhibitory signaling are also associated with excitotoxicity and neuroinflammation.
Neurons exposed to the inflammatory cytokine interleukin-1b (IL-1b) increase surface expression of c-aminobutyric acid type A receptors (GABA A Rs) (Serantes et al. 2006) , suggesting that inhibitory neurotransmission can be influenced by inflammatory pathways. Excessive up-regulation of GABAergic signaling in response to inflammatory and excitotoxic stress impairs cognitive function. For example, in models of stroke, excess GABAergic tone impairs network recovery (Orfila et al. 2017) and in schizophrenia patients, increased synaptic a2 subunitcontaining GABA A Rs are associated with cognitive dysfunction (Impagnatiello et al. 1998; Lewis et al. 2004; Guidotti et al. 2005) . Up-regulation of GABAergic synaptic markers also occurs following prolonged exposure to HIV neurotoxins, suggesting that excess inhibitory signaling may be involved in HAND as well (Fitting et al. 2013; Hargus and Thayer 2013) . At present, how GABAmediated inhibition is regulated during HIV-induced neuroinflammation remains unknown.
HAND pathogenesis occurs primarily through an indirect mechanism mediated by the release of toxic agents, such as the HIV envelope protein gp120. HIV gp120 is shed by infected cells (Kaul et al. 2001) , elicits neurotoxicity at picomolar concentrations (Meucci and Miller 1996; Kim et al. 2011; Zhou et al. 2017) , and has been detected in the brains of patients with HAND (Jones et al. 2000) . HIV gp120 evokes synaptic and behavioral deficits in vivo that mimic significant aspects of HAND (Toggas et al. 1994; Thaney et al. 2018) . In this study, we used an in vitro model to study changes in inhibitory synapses during exposure to the neuroinflammatory stimulus HIV gp120. The envelope protein evoked the release of IL-1b from microglia. The resulting stimulation of IL-1 receptors on neurons activates a Src and NMDA receptor pathway that increases the number of inhibitory synapses. This pathway overcame a basal suppression of inhibitory synapse number mediated by p38 MAPK. Recognizing that these two pathways regulate inhibitory synapse number, and that there is crosstalk between these pathways, provides insight into the neuronal response to inflammation and may guide the development of therapeutics targeting inhibitory signaling in HAND. (catalog number: 1962) ; 6-Cyano-7-nitroquinoxaline-2,3-dione disodium (CNQX) (catalog number: 1045); bicuculline methiodide; and tetrodotoxin (TTX) (catalog number: 1069) were from Tocris Bioscience (Bristol, UK); 4-Ethyl-2(p-methoxyphenyl)-5-(4ʹ-pyridyl)-IH-imidazole (SB202474) was from Millipore Sigma (catalog number: 559387; St. Louis, MO, USA). Dulbecco's modified Eagle's medium (DMEM) (catalog number: 31053), Hanks' balanced salt solution (catalog number: 14175), fetal bovine serum (catalog number: 26140), horse serum (catalog number: 16050), and penicillin/streptomycin (catalog number: 15140) were from ThermoFisher Scientific (Carlsbad, CA, USA). The expression vector for GPHN.FingR-eGFP, pCAG-GPHN.FingR-eGFP, was generated by Don Arnold's laboratory and obtained from Addgene (catalog number: 46296; Cambridge, MA, USA). The expression vector for synapsin-driven tdTomato was generated by inserting tdTomato from pLVX-tdTomato-N1 (catalog number: 632563; ClontechTakara Bio, Mountain View, CA, USA) into the pSyn backbone of pSyn-PSD95-GFP provided by Kirill Martemyanov (Scripps Research Institute, Jupiter, FL, USA). The plasmid for RapR-p38 expression (pCMV5-Flag-RapR-p38) was generated in Klaus Hahn's laboratory and obtained from Addgene (catalog number: 25935). HIV-1 gp120 IIIB was from the National Institutes of Health (NIH) AIDS Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH (catalog number:11784).
Materials and methods

Materials
Cell culture
All animal care and experimental procedures were performed following the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health. Ethical approval was granted by the Institutional Animal Care and Use Committee of the University of Minnesota (protocol 1612-34372A). Primary hippocampal cultures were derived from fetal Sprague-Dawley rats (RRID:MGI:5651135, Charles River, Wilmington, MA, USA) as described previously . Rats were euthanized by CO 2 inhalation then hippocampi from embryonic day 17 fetuses were dissected and placed in Ca 2+ and Mg 2+ -free Hanks' balanced salt solution. Hippocampi were dissociated by trituration with flame-narrowed Pasteur pipettes of decreasing aperture in DMEM supplemented with 10% fetal bovine serum and penicillin/ streptomycin (100 U/mL and 100 mg/mL, respectively). Cells were plated onto Matrigel-coated (150 lL, 0.2 mg/mL, BD Biosciences, Billerica, MA, USA) glass-bottomed Petri dishes. Cultures were kept in a humidified atmosphere of 10% CO 2 and 90% air (pH 7.4) at 37°C. Culture media were exchanged on days 1 and 8 in vitro with DMEM supplemented with 10% horse serum and penicillin/ streptomycin. All cultures were maintained for 12-16 days in vitro prior to use in experiments. These cultures contain 24 AE 4% neurons, 55 AE 4% astrocytes, and 13 AE 6% microglia .
Transfection
Cultures were transfected using a previously described calcium phosphate procedure . After 11 or 12 days in vitro, culture media were exchanged with DMEM containing 1 mM kynurenic acid, 10 mM MgCl 2 , and 5 mM HEPES. A DNA/ calcium phosphate precipitate containing 0.5 lg of total plasmid DNA per well was allowed to form at 23°C for 1.5 h, then added drop wise to the cells. After a 1 h incubation, cells were washed twice with DMEM supplemented with 10 mM MgCl 2 and 5 mM HEPES and conditioned media saved at the beginning of the procedure were returned to the cells. Experiments were started 2-3 days after transfection.
Confocal imaging and image processing
Confocal imaging and image processing were performed as previously described . Petri dishes containing transfected cells were placed in an incubator (LCI, Seoul, Korea; 37°C and 10% CO 2 ) on the stage of an inverted laser scanning confocal microscope (Nikon A1, Melville, NY, USA) and imaged with a 60 9 (1.4 numerical aperture) oil-immersion objective. Optical sections spanning 9 lm (1 lm per step) in the z-dimension were collected and combined into a maximum z-projection. GFP was excited at 488 nm and emission collected from 500 to 550 nm. TdTomato was excited at 561 nm and emission collected from 570 nm to 620 nm. After imaging, cells were returned to the cell culture incubator and the coordinates of the computer-controlled stage saved to allow repeated imaging of the same cell at later time points. An algorithm written in MetaMorph 7 (RRID:SCR_002368, San Jose, CA, USA) was used to count the GFP puncta in an unbiased manner (Waataja et al. 2008) . A threshold 0.25 times the standard deviation above the image mean was applied to the red image creating a 1-bit image. This binary image was used as a mask via a logical AND function with the green channel maximum zprojection. A top-hat filter (80 pixels) was applied to the masked green image. A threshold set 1.5 standard deviations above the mean intensity inside the mask was then applied to the contrast-enhanced image. Punctate structures between 12 and 80 pixels (0.13-0.86 lm 2 ) were counted as post-synaptic densities. Changes in the number of GPHN.FingR-GFP puncta from two to three microscopic fields from a single dish were averaged and considered an individual sample (n = 1).
Electrophysiology
Electrodes were pulled using a horizontal micropipette puller (P-87; Sutter Instruments) from glass capillaries (Narishige). Pipette resistance was 3-5 MΩ. Miniature inhibitory post-synaptic currents (mIPSCs) were recorded with the following extracellular solution (in mM): 140 NaCl, 5 KCl, 9 CaCl, 6 MgCl, 5 glucose, and 10 HEPES, pH adjusted to 7.4 with NaOH. The intracellular recording solution was composed of (in mM): 140 KCl, 0.2 EGTA, 10 HEPES, 10 glucose, 5 MgATP, and 0.3 NaGTP, pH adjusted to 7.2 with KOH. Whole-cell voltages were amplified with an AxoPatch 200B (Molecular Devices), low-pass filtered at 2 kHz, and digitized at 10 kHz with a Digidata 1322A digitizer and pClamp software (Molecular Devices). Cells with series resistance over 25 MΩ were excluded from analysis. Cells were voltage clamped at -70 mV in the presence of 3 lM CNQX, 50 lM APV, and 100 nM TTX. Data were analyzed with miniAnalysis software (Synaptosoft) using a threshold of 15 pA.
Statistics
All data are presented as mean AE SEM. Data distributions were determined using the D'Agostino-Pearson normality test and homogeneity of variances determined using Bartlett's test; all statistical tests were performed on normally distributed data of equal variance. Student's t-test (unpaired two-tailed) was used for statistical analysis in two-group comparison. For comparison among multiple groups, one-way or two-way ANOVAs were performed with Tukey's post hoc test. Time course data were analyzed with a twoway repeated measures ANOVA. Statistical significance was defined as p < 0.05. Sample sizes were not statistically predetermined but conform to similar studies. A test for outliers was not performed in this study. For imaging inhibitory synapses, the change in puncta from two to three fields from a single dish was averaged and considered as n = 1. Imaging experiments included data from at least eight dishes from three to five different cell culture platings. Gephyrin puncta were counted using an objective image processing algorithm that obviated the need to blind the experimenter. No other blinding methods were employed in this study. All statistical analyses were performed using Prism, GraphPad 7 (La Jolla, CA 92037 USA).
Results
HIV gp120IIIB increases the number of inhibitory synapses
The number of inhibitory synapses between hippocampal neurons in culture was determined by counting puncta produced by expression of a fluorescent antibody-like protein in live cells. Rat hippocampal cultures were transfected with plasmids that express a red fluorescent protein (tdTomato) to resolve cell morphology and a recombinant intrabody (GPHN.FingR-eGFP) that binds to gephyrin, a scaffolding protein located at the post-synaptic terminal of inhibitory synapses (Tyagarajan and Fritschy 2014) (Fig. 1a) . Previous studies have shown that GPHN.FingR-eGFP expressed in rat neurons labels synaptic structures as indicated by colocalization of intrabody-enhanced green fluorescent protein (EGFP) puncta with endogenous gephyrin (Gross et al. 2013) . To quantify the number of inhibitory synapses, an image processing algorithm was used to count fluorescent puncta meeting size and intensity criteria that were in contact with a binary mask created from the tdTomato image (Fig. 1a) . Functional analysis revealed that the number of labeled gephyrin puncta correlates with the frequency of mIPSCs (Fig. 1b) indicating that fluorescent puncta identify functional synapses. To determine whether gp120 influences the number of inhibitory synapses, transfected neurons were imaged before (0 h) and 4 and 24 h after treatment with 600 pM gp120. Treatment with gp120 for 24 h increased the number of intrabody-labeled gephyrin puncta by 18 AE 5% compared with untreated control ( Fig. 1c and d ). The number of inhibitory synapses was unchanged after 4 h exposure to gp120, indicating that the increase occurred in a timedependent manner. To determine if gp120 affected neuronal survival, we calculated the percentage of neurons that retained tdTomato fluorescence at the 24 h time point for the experimental cohorts included in Fig. 1d . In the untreated control group, 84 AE 4% of neurons survived; in gp120-treated group, 89 AE 9% of the neurons survived, indicating that treatment with gp120 did not elicit significant neuronal death (unpaired two-tailed t-test; t (8) = 0.48, p = 0.65, n = 5). This result is consistent with a previous cell survival study from our laboratory using a propidium iodide uptake Fig. 1 gp120 increases the number of inhibitory synapses. (a) Representative confocal images of a neuron-expressing GPHN.FingR-eGFP and tdTomato were acquired and processed as described in Methods. Identified gephyrin puncta (yellow) were dilated and overlaid on the tdTomato maximum projection (Processed) for display purposes. Insets are enlarged images of the boxed regions. Scale bars represent 10 lm. (b) The number of gephyrin puncta correlates with the frequency of miniature inhibitory post-synaptic current (mIPSCs) (r (4) = 0.95, p = 0.004, n = 6; data from two independent cell preparations). (c) Representative processed confocal images and (d) plot showing time-dependent increase in the number of gephyrin-labeled inhibitory synapses following treatment with gp120 (600 pM) (two-way repeated measures ANOVA; F (2, 26) = 6.61, p = 0.005, n = 14; data from five independent cell preparations). (e)Treatment with 600 pM gp120 for 24 h increased the number of gephyrinlabeled inhibitory synapses. Heat-inactivated gp120 (HI-gp120) did not affect the number of inhibitory synapses. (One-way ANOVA; F (2,29) = 9.43, p = 0.0007, n = 10 for control and HI-gp120 group; n = 12 for gp120=treated group; data from three independent cell preparations). Insets are enlarged images of the boxed regions. Scale bars represent 10 lm. Data are expressed as mean AE SEM. Two-way repeated measures ANOVA or one-way ANOVA was followed with Tukey's post hoc test, **p < 0.01, compared with control group (n = number of individual dishes in each group).
assay that found 600 pM gp120 did not induce significant neuronal death until after exposure for 48 h (Kim et al. 2011) . To determine if the effects of gp120 required intact tertiary structure and also to exclude a possible contribution from endotoxin contamination in the gp120 stock, transfected neurons were imaged before (0 h) and 24 h after treatment with 600 pM gp120 or heat-inactivated gp120 (HIgp120, 95°C for 1 h). Treatment with HI-gp120 did not increase the number of inhibitory synapses (Fig. 1e) .
HIV gp120 activates CXCR4 to release IL-1b from microglia to up-regulate inhibitory synapses The IIIB strain of the HIV-1 envelope protein gp120 binds to its co-receptor C-X-C chemokine receptor type 4 (CXCR4) and CD4 to initiate viral entry. The interaction of gp120 with CXCR4 activates microglia to release inflammatory cytokines that affect neurons (Viviani et al. 2006; Kim et al. 2011; Zhang and Thayer 2018) . To determine whether this receptor was involved in the gp120-induced increase in the number of intrabody-labeled gephyrin puncta, we co-treated neuronal cultures with the CXCR4 antagonist AMD3100 (1 lM) and gp120. AMD3100 prevented the increase in gephyrin puncta evoked by 24 h treatment with gp120 (Fig. 2a) . CXCR4 is expressed in microglia, astrocytes, and neurons (Bonavia et al. 2003) , which are all present in our primary hippocampal cultures. To test whether microglia were necessary for the effects of gp120, we eliminated microglia from the culture by treating with Leucine-Methyl-Ester (LME) (25 mM for 1 h followed by DMEM wash, or DMEM for 1 h followed by DMEM wash for control) 24 h prior to treating with gp120. LME treatment reduced the number of microglia by 95% compared with DMEM wash controls, as determined by immunocytochemistry with the Ox-42 antibody. Elimination of microglia prior to treatment with gp120 prevented the increase in intrabody-labeled gephyrin puncta compared with DMEM wash controls (Fig. 2b) .
The interaction of gp120 with CXCR4 on microglia can evoke the release of inflammatory cytokines such as IL-1b. IL-1b increases the amplitude of evoked IPSCs (Hellstrom et al. 2005) and surface expression of functional GABA A Rs Fig. 2 gp120-evoked release of IL-1b from microglia up-regulates the number of inhibitory synapses. (a) CXCR4 antagonist, AMD3100 (1 lM), inhibits gp120-induced (600 pM) increases in the number of intrabody-labeled gephyrin puncta (24 h) relative to initial puncta count (0 h) (two-way ANOVA; F (1,42) = 9.45, p = 0.004, n = 11 for control; n = 12 for gp120-treated groups; data from four independent cell preparations). (b) Removal of microglia by 1 h treatment with 25 mM LME blocks gp120-induced increases in the number of inhibitory synapses (two-way ANOVA; F (1,53) = 6.10, p = 0.02; data from five independent cell preparations) compared with Dulbecco's modified Eagle's medium (DMEM) wash (n = 14). (c) IL-1b (3 ng/ mL for 24 h) alone increases the number of inhibitory synapses (unpaired two-tailed t-test; t (16) =4.8, p = 0.0002, n = 9; data from three independent cell preparations). (d) IL-1ra (1 lg/mL) blocks the gp120-induced increase in the number of inhibitory synapses (two-way ANOVA; F (1,36) = 8.03, p = 0.008, n = 10; data from four independent cell preparations). Data are expressed as mean AE SEM. Two-way ANOVAs were followed by Tukey's post hoc test, *p < 0.05, **p < 0.01, ***p < .001 compared with untreated control. ( Serantes et al. 2006) . Here, we examined the role of IL-1b in the gp120-induced up-regulation of inhibitory synapses. Treatment with IL-1b (3 ng/mL) for 24 h significantly increased the number of intrabody-labeled gephyrin puncta by 24 AE 4% compared with control (Fig. 2c) . Thus, IL-1b mimics the effects of gp120 on the number of inhibitory synapses. To determine whether the gp120-induced increase in inhibition is mediated by IL-1b, cultures were co-treated with 1 lg/mL IL-1 receptor antagonist (IL-1ra) and gp120 (600 pM). IL-1ra prevented the gp120-induced increase in the number of intrabody-labeled gephyrin puncta (Fig. 2d) . Collectively, these results indicate that gp120 activates CXCR4 on microglia to stimulate a neuroinflammatory pathway to release IL-1b that acts on its receptor to alter the number of inhibitory synapses.
Basal p38 MAPK activity suppresses the number of inhibitory synapses IL-1 receptor activation was previously shown to couple with the p38 mitogen-activated protein kinase (p38 MAPK) pathway to inhibit long-term potentiation (Kelly et al. 2003) and up-regulation of this pathway is also reported to induce synaptic changes associated with neurodegenerative disease (Sama and Norris 2013 ). Therefore, we tested whether inhibition of p38 affected the number of inhibitory synapses. Treatment with SB203,580 (10 lM), a selective p38 MAPK inhibitor, alone induced an increase in gephyrin puncta (Fig. 3a, b) . This increase was not observed with the inactive analog SB202474 (10 lM) (Fig. 3c) , and was also observed with a second p38 inhibitor, SB239063 (10 lM) (Fig. 3d) . These data suggest that p38 tonically suppresses GABAergic neurotransmission by decreasing the number of inhibitory synapses. To further explore the role of p38, we employed a genetic approach. RapR-p38 is a genetically modified p38 kinase that acts as a dominant negative when expressed in the presence of wild-type p38. RapR-p38 is activated by rapamycin, enabling regulation of p38 activity independent of its upstream physiological signaling pathway (Karginov et al. 2010) . In cells expressing RapR-p38, tdTomato, and GPHN.FingR-eGFP, rapamycin treatment reduced the number of inhibitory synapses by 19 AE 3% compared with those not treated with rapamycin (Fig. 3e) . Thus, activation of p38 is sufficient to suppress the formation of new inhibitory synapses under basal conditions. HIV gp120 activates Src and GluN2A-containing NMDARs to increase the number of inhibitory synapses IL-1b stimulates phosphorylation of NMDARs by Src family kinases (SFKs) (Viviani et al. 2003 (Viviani et al. , 2006 . Over-activation of NMDARs leads to an increase in the number of inhibitory synapses following exposure to the HIV protein Tat (Hargus and Thayer 2013) . Thus, to determine the downstream mechanism for the gp120-induced increase in inhibitory synapses, we used the selective SFK inhibitor, PP2, to determine whether the gp120-induced increase in inhibitory post-synaptic sites is mediated by SFKs. PP2 (10 lM), but not the inactive analog PP3 (10 lM), prevented the gp120-induced increase in intrabody-labeled gephyrin puncta (24 h) (Fig. 4a-c) . The SFKs Src and Fyn have been shown to regulate inhibitory synaptic transmission (Ohnishi et al. 2011) . To determine the specific SFK responsible for the gp120-induced increase in inhibitory synapses and to compliment the pharmacological approach with a genetic method, cultures were co-transfected with expression plasmids for tdTomato and gephyrin intrabody with or without plasmids that encode dominant-negative Src (DN-Src) or dominant-negative Fyn (DN-Fyn) (Mariotti et al. 2001) . Gp120 treatment increased the number of intrabody-labeled gephyrin puncta in both untreated neurons and neuronsexpressing DN-Fyn (Fig. 4d) . However, in neurons-expressing DN-Src, gp120 failed to induce a significant increase in inhibitory synapses (Fig. 4d) . These data suggest that Src mediates the gp120-induced increase in the number of inhibitory synapses.
Src phosphorylates NMDARs increasing their activity (Kohr and Seeburg 1996) . Thus, we tested whether NMDA receptors mediate the gp120-induced increase in inhibition. In previous work, we found that synaptic changes induced by HIV proteins were mediated by GluN2A-containing NMDARs (Hargus and Thayer 2013; Shin and Thayer 2013) . TCN201 (10 lM), an inhibitor of GluN2A-containing NMDARs, prevented the gp120-induced increase in intrabody-labeled gephyrin puncta (24 h) (Fig. 5a) . Increases in the number of inhibitory synapses could result from potentiated GABA A R function, insertion of intracellular GABA A Rs, or gene expression and production of new receptors (Kneussel and Hausrat 2016) . To determine whether the gp120-induced increase in inhibition requires gene expression, we pre-treated the culture with the protein synthesis inhibitor, cycloheximide (10 lM). Cycloheximide prevented the gp120-induced increase in intrabody-labeled puncta (Fig. 5b) . These data indicate that translation following activation of Src and GluN2A-containing NMDARs is required for the gp120-induced increases in intrabodylabeled gephyrin puncta.
Discussion
Elevated inhibitory signaling is associated with many neurodegenerative conditions (Fernandez et al. 2007; Hines et al. 2012; Wu et al. 2014) . In this study, we examined how inhibitory synapses are affected in an in vitro model of HIVassociated neuroinflammation. Using an imaging-based approach to quantify GABAergic synapses in living neural networks, we found that gp120, a potent neurotoxin that in vivo mimics significant aspects of HAND (Toggas et al. 1994) , increased the number of inhibitory synapses between hippocampal neurons. The effects of gp120 were mediated (10 lM) alone increases the number of intrabody-labeled gephyrin puncta (24 h) relative to untreated (unpaired two-tailed t-test; t (16) = 2.21, p = 0.04, n = 9; data from three independent cell preparations). (c) SB202474 (10 lM), an inactive analog of SB203580, does not affect the gp120-induced (600 pM) increase in the number of intrabody-labeled gephyrin puncta (24 h) (unpaired two-tailed ttest; t (18) = 0.004, p = 1, n = 10; data from three independent cell preparations). (d) The number of intrabody-labeled gephyrin puncta is increased by 24 h treatment with SB239063 (10 lM), a p38 MAPK inhibitor (unpaired two-tailed t-test; t (14) = 4.95, p = 0.0002, n = 8; data from three independent cell preparations). (e) Treatment with rapamycin (200 nM) decreases the number of inhibitory synapses in cells expressing RapRp38 (unpaired two-tailed t-test, t (14) = 3.71, p = 0.002; data from three independent cell preparations) but not untreated cells (unpaired two-tailed t-test, t (14) =0.43, p = 0.7; data from three independent cell preparations) (n = 8). Data are expressed as mean AE SEM, *p < 0.05, **p < 0.01, ***p < .001, compared with control (n = number of individual dishes in each group).
by the release of the inflammatory cytokine IL-1b from microglia, consistent with previous studies (Louboutin et al. 2010; Kim et al. 2011) , and suggesting that the synaptic changes we observed are broadly relevant to neuroinflammatory conditions. Stimulation of IL-1 receptors activated a Src-NMDAR pathway to increase GABAergic synapses. This pathway reversed a tonic p38 MAPK-mediated suppression of inhibitory synapse number, suggesting that during neurotoxic challenge this up-regulation overcomes a basal regulatory process. This novel dual mechanism of control provides insights into the regulation of inhibitory synapses at rest and during neuroinflammation that may identify approaches to improve cognitive function in HAND.
This study is based on a synaptic imaging approach. The method uses a recombinant antibody-like protein (intrabody) linked to EGFP, which binds to the post-synaptic scaffolding protein gephyrin and forms fluorescent clusters around inhibitory synapses. Intra-bodies do not induce the formation of new inhibitory synapses as may occur with EGFP gephyrin fusion proteins previously used (Hargus and Thayer 2013) . Electrophysiological analysis demonstrated that the labeled puncta number correlates with mIPSC frequency, confirming that intrabody-labeled sites represent functional inhibitory synapses. The principal advantage of the live-cell synaptic imaging approach is synapse counts from the same region of interest can be imaged before and after treatment enabling synapse count, which varies considerably between cells, to be normalized to its pre-treatment value. While we have not performed in vivo validation for the specific synaptic changes described in this report, the loss of excitatory synapses induced by HIV proteins using this same cell culture model was replicated in vivo in experiments in which pharmacological rescue of synapses also reversed cognitive impairment (Raybuck et al. 2017) . Thus, synaptic changes observed in this mixed glial and neuronal culture have effectively predicted similar outcomes in vivo.
HIV gp120 has been detected in the brains of HIV-infected patients with dementia using immunohistochemistry (Jones et al. 2000) . We are not aware of a quantitative measure of gp120 levels in brain or cerebrospinal fluid (CSF) of HIV patients. However, high levels of anti-gp120 antibody have been detected in the CSF compared with serum in HIV patients with cognitive deficits, suggesting accumulation of gp120 in the CSF (Trujillo et al. 1996) . The levels of gp120 in the plasma, serum, and other tissues from HIV patients range from 0.3 to 92 ng/mL depending on the tissue (Oh Fig. 5 Up-regulation of the number of inhibitory synapses requires GluN2A-containing NMDARs and protein synthesis. (a) TCN201 (10 lM), an antagonist for GluN2A-containing NMDARs blocks the gp120-induced increase in the number of intrabody-labeled gephyrin puncta (two-way ANOVA; F (1,42) = 10.93, p = 0.002, n = 12 for untreated groups; n = 11 for TCN201-treated groups; data from four independent cell preparations). (b) The protein synthesis inhibitor cycloheximide (CHX) (10 lM) blocks the gp120-induced increase in the number of inhibitory synapses (two-way ANOVA, F (1,39) =9.29, p = 0.004, n = 11 for untreated control; n = 10 for untreated gp120 group; n = 11 for CHX treated groups; data from four independent cell preparations). Data are expressed as mean AE SEM. Two-way ANOVAs were followed by Tukey's post hoc test, *p < 0.05, **p < 0.01 compared with control. ## p < 0.01, ### p < 0.001 compared with gp120 alone (untreated) (n=number of individual dishes in each group). showing that the Src family kinase inhibitor PP2 (10 lM) reduced gp120-induced increase in the number of intrabody-labeled gephyrin puncta (twoway ANOVA; F (1,45) = 5.10, p = 0.03, n = 13 for untreated control; n = 12 for other groups; data from five independent cell preparations). (c) PP3 (10 lM), an inactive analog of PP2, does not affect the gp120-induced (600 pM) increase in the number of inhibitory synapses (two-way ANOVA; F(1, 43) = 0.012, p = 0.9, n = 13 for untreated control; n = 12 for untreated gp120 group; n = 12 for PP3 control group; n = 10 for PP3 gp120 group; data from five independent cell preparations). (d) gp120 induces an increase in the number of intrabody-labeled gephyrin puncta in untreated cultures (t (25) = 3.47, p = 0.002, n = 13 for untreated control; n = 14 for untreated gp120 group) and cultures expressing dominant-negative Fyn (t (23) = 2.58, p = 0.02, n = 13 for Fyn control group; n = 12 for Fyn gp120 treated group), but in cultures expressing dominant-negative Src the gp120-induced response was blocked (unpaired two-tailed t-test; t (24) = 1.04, p = 0.3, n = 13; data from six independent cell preparations). Twoway ANOVAs were followed by Tukey's post hoc test, *p < 0.05, **p < 0.01 compared with control. # p < 0.05 compared with gp120 alone (untreated) (n = number of individual dishes in each group).
et al. 1992; Santosuosso et al. 2009; Rychert et al. 2010) . Thus, the 600 pM (72 ng/mL) concentration of gp120 used in this study is comparable to that found in the tissues of HIV-infected individuals. HIV gp120 activated CXCR4 to evoke the release of IL-1b from microglia. This observation is consistent with the tropism of the IIIB strain of gp120 which binds to CXCR4 (Moore et al. 1997; Islam et al. 2013) . Recombinant gp120 IIIB has previously been demonstrated to induce release of inflammatory cytokines including IL-1b from human monocytes (Clouse et al. 1991) . HIV IIIB is a widely studied laboratory strain that was not isolated from the CNS of HAND patients. However, CCR5 tropic gp120 has been found in HIV-infected brain and induces an inflammatory response similar to the gp120 IIIB -evoked response described here, including release of IL-1b in both rodent brain and cultured human microglia (Ashraf et al. 2014; Walsh et al. 2014) . Thus, the IL-1b-dependent increase in inhibitory synapses evoked by the CXCR4 preferring gp120 used here would also be predicted to result from exposure to CCR5 preferring strains. Furthermore, neuronal injury resulting from expression of gp120 IIIB is prevented in CCR5 knockout mice, suggesting an indirect pathologic role for CCR5 in CXCR4-initiated neuroinflammation (Maung et al. 2014) .
HIV neurotoxicity is indirect resulting from the release of viral proteins and inflammatory cytokines from infected microglia and macrophages (Ellis et al. 2007; Saylor et al. 2016) . For productive infection, HIV gp120 interacts with a chemokine receptor (CXCR4 or CCR5) and CD4 to gain cell entry (Deng et al. 1996; Berger et al. 1999) . Rodent models like the cell culture studied here cannot be infected by HIV because they lack CD4 expression. However, gp120 can bind to and interact with chemokine receptors in the absence of CD4 (Hesselgesser et al. 1997; Kaul and Lipton 1999) . The gp120 IIIB used in this study binds to rodent CXCR4 and elicits the release of inflammatory cytokines (Clouse et al. 1991; Brelot et al. 1997; Bagetta et al. 1999; Bezzi et al. 2001) . Thus, results of this study are particularly relevant to gp120 shed from infected cells that then acts on additional non-infected cells. We have previously shown that treatment of the same neuron-glia co-cultures used here with 600 pM gp120 increased expression of IL-1b mRNA and release of IL-1b protein (Kim et al. 2011; Zhang and Thayer 2018) . The concentration of IL-1b released into the cell culture media was 70 pg/mL, which likely underestimates the local concentration in the culture monolayer and is lower than the concentration employed in this study to increase the number of inhibitory synapses. Treating the culture with threoninelysine-proline, which blocks activation of microglia, inhibits gp120-evoked IL-1b release, suggesting that microglia are the primary source for IL-1b (Kim et al. 2011) . The gp120-evoked release of IL-1b replicates one of the neuroinflammatory mechanisms thought to mediate HAND and is consistent with studies from other laboratories showing that the highly potent effects that result from prolonged exposure to low concentrations (picomolar) of the envelope protein is indirect (Meucci and Miller 1996; Viviani et al. 2006; Medders et al. 2010; Kim et al. 2011; Yang et al. 2013) . Up-regulation of inhibitory synapses was blocked selectively by expression of dominant-negative Src in neurons, suggesting that key steps in the downstream regulatory pathways are located within neurons. Neurons express IL-1Rs (Vezzani et al. 2011) but astrocytes also exhibit IL-1 receptor signaling (Ravizza and Vezzani 2006) and could contribute to the effects described here. gp120-induced potentiation of NMDA receptor function and subsequent loss of excitatory synapses are also mediated by an IL-1b-induced pathway , consistent with the key role of IL1b in HIV gp120-induced neuronal injury. IL-1b mRNA and protein expression levels are increased significantly in the brain tissues of HIV-positive patients (Persidsky and Gendelman 1997; Xing et al. 2009; Walsh et al. 2014) . In HIV-1 encephalitis patients, the expression of IL-1b is significantly higher compared with HIV-seropositive or -seronegative patients without HIV-1 encephalitis (Zhao et al. 2001) . A slightly modified form of recombinant human IL-1ra is currently being tested in a clinical trial for HAND (ClinicalTrials.gov Identifier: NCT02527460). The signaling pathway activated by gp120 and described here might reveal additional targets relevant to HAND pharmacotherapy.
The gp120-evoked increase in the number of inhibitory synapses appears to be mediated by a homeostatic plasticity mechanism to counteract excessive excitation (Pozo and Goda 2010; Green et al. 2018 ). We did not detect significant cell death during a 24 h exposure to gp120, although others have described a 23-55% loss of neurons during a 24-72 exposure to gp120 concentrations ranging from 200 pM to 100 nM (Medders et al. 2010; Avdoshina et al. 2016; Liu et al. 2016) . Our results suggest that there is an early adaptive, possibly protective, response that is initiated by the same potentiation of NMDARs that triggers the cell death process. HIV gp120 potentiated NMDAR function via activation of the tyrosine kinase Src, a process known to sensitize the NMDAR to activation by glutamate (Viviani et al. 2006; Krogh et al. 2014; Green and Thayer 2016; Zhang and Thayer 2018) . In hypothalamic neurons, IL-1 receptors couple to Src via MyD88-dependent production of ceramide (Davis et al. 2006) and in hippocampal neurons this pathway impairs spine structural remodeling (Tong et al. 2018) . IL-1b is pro-convulsive and is thought to mediate some of the seizure promoting effects of inflammation (Rijkers et al. 2009 ). We have shown previously that following exposure to agents that potentiate NMDARs via Src activation, the synaptic network undergoes a series of adaptive changes over the next 18-24 h (Kim et al. 2008b (Kim et al. , 2011 Green and Thayer 2016; Zhang and Thayer 2018) . These adaptive mechanisms, including loss of excitatory synapses, appear to be part of a homeostatic plasticity mechanism that is not part of the neuronal death process (Shin et al. 2012; Raybuck et al. 2017; Green et al. 2018) . We posit that the gp120-induced increase in inhibitory synapses is part of a coping mechanism that occurs during 24 h treatment with agents that potentiate NMDARs. Activation of GluN2A-containing NMDARs appears to regulate synaptic plasticity and be neuroprotective (Liu et al. 2007; Baez et al. 2018) , whereas activation of GluN2B-containing NMDARs is associated with neuronal death pathways (Taghibiglou et al. 2009; Tu et al. 2010) . The increase in inhibitory synapses was dependent on activation of GluN2A-containing NMDARs and protein synthesis, consistent with previous reports showing that activation of synaptic NMDARs triggers expression of pro-survival genes (Bading 2017 ) and the idea that increased synaptic inhibition attenuates excitotoxicity. Thus, synaptic changes may be a mechanism to cope with over activation of NMDARs (Green et al. 2018) . This study supports the idea that activation of potentiated GluN2A-containing NMDARs increases inhibitory synapse number as an adaptive mechanism to counteract excess excitation and promote neuronal survival.
Gp120-induced neuroinflammation and subsequent activation of IL-1Rs increases the formation of inhibitory synapses, an adaptive process that might improve neuronal survival at the cost of impaired function. Increased inhibitory tone suppresses long-term potentiation in the hippocampus (Arima-Yoshida et al. 2011; Schreurs et al. 2017) . Enhanced GABAergic inhibitory signaling is associated with cognitive deficits in many neurodegenerative conditions. For example, excess GABA release from reactive astrocytes impairs memory in mouse models of Alzheimer's disease (Jo et al. 2014 ) and increased synaptic a2-containing GABARs receptors are associated with memory dysfunction in schizophrenia (Lewis et al. 2004) . Excessive inhibition of GABA transporters, a target of some anti-epileptic drugs, produces cognitive deficits (Cavanna et al. 2010) . Reversing the synaptic adaptations that occur under neuroinflammatory and excitotoxic conditions by recovering lost excitatory synapses and reducing up-regulated inhibitory synapses may provide a novel strategy to improve cognitive function (Ryan et al. 2015; Calvo-Flores Guzman et al. 2018) .However, if this formof synapticscaling isa coping mechanism to improve neuronal survival, then it will be important to consider the potential adverse consequences of attenuating this protective mechanism when designing pharmacotherapies.
Inhibition of p38 MAPK in na€ ıve cultures increased the number of inhibitory synapses and activating a mutant form of p38 expressed in hippocampal neurons decreased the number of inhibitory synapses. This is consistent with previous work in rat and mouse hippocampal neurons showing that p38 activated phosphatidylinositol 3-kinase, protein phosphatase 1, and dynamin GTPase to reduce trafficking of GABA A Rs to the cell surface (Pribiag and Stellwagen 2013) . These results indicate that there is basal activation of a p38 MAPK pathway in hippocampal neurons that constrains the number of inhibitory synapses. Medders et al. (Medders et al. 2010) conducted an extensive analysis of p38 MAPK activation in a similar mixed neuron-glia coculture. Consistent with our results they found p38 activated in neurons under basal conditions. They also found that gp120 activated p38 in microglia, possibly as a step in the secretory process. We did not address the role of p38 in microglia, although such a role is not inconsistent with our finding that microglial activation is upstream of the neuronal response. Activation of IL-1Rs stimulates p38 MAPK in hippocampal neurons (Tong et al. 2012) . Thus, both p38 MAPK and Src-NMDAR pathways are up-regulated and coordinately regulate the number of inhibitory synapses in the presence of gp120. The Src-NMDAR pathway is the dominant signal at the synapse in this condition. It appears that normal homeostatic balance between the two pathways is disrupted under neuroinflammatory conditions. This report shows for the first time that gp120 increases the number of inhibitory synapses through a neuroinflammatory mechanism initiated by IL-1b. The number of inhibitory synapses is coordinately regulated by both p38 MAPK and Src-NMDAR pathways with the Src-NMDAR pathway dominating under inflammatory conditions. Identifying the mechanisms that control the number of inhibitory synapses provides a better understanding of the pathogenesis of HAND and may guide the development of therapeutics targeting inhibitory signaling during neuroinflammation.
